RNA Therapeutics Market Analysis

RNA Therapeutics Market Analysis

To get key market trends

  Download Free Sample

Based on product, the RNA therapeutic market is segmented into vaccines and drugs. The vaccines segment held largest business share of 71.7% in 2023.

• High market share can be attributed to the ability of RNA vaccines to induce robust and specific immune responses. Also, the success of RNA vaccines in combating infectious diseases, especially COVID-19 virus, has further propelled the market share of this segment.

   

• Further, with ongoing advancements in RNA therapeutic research and the increasing recognition of their potential in preventing a wide array of diseases, the vaccines segment is poised to maintain its dominance, contributing significantly to the market progress.

Based on type, the RNA therapeutics market is classified into mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics, siRNA (small interfering RNA) therapeutics, and other types. The mRNA therapeutics segment was valued at USD 12.6 billion in 2023.

• mRNA-based therapies exhibit a remarkable versatility, as they can be designed and tailored to address a diverse range of medical conditions, including infectious diseases, cancers, and genetic disorders.
  
   
• Availability of several mRNA vaccines in pipeline and clinical trials for wide applications will further enhances its segmental growth. Moreover, the approval of COVID-19 mRNA vaccines such as the Pfizer-BioNTech and Moderna significantly increased the confidence in the efficacy and safety of mRNA technology, further boosting the segmental growth.

   

Based on indications, the RNA therapeutics market is segmented into infectious diseases, hereditary/genetic diseases, autoimmune disorders, and other indications. The infectious diseases segment is anticipated to grow at a CAGR of 5.5% between 2024 and 2032 to reach USD 19.4 billion by 2032.

• Rising global burden of infectious diseases, coupled with the emergence of new and drug-resistant pathogens, has increased the adoption of advanced therapeutic interventions including RNA therapeutics for the treatment.

   

• Also, rapid advancements in RNA-based technologies, including messenger RNA (mRNA) vaccines and siRNA therapies is expected to contribute significantly to the segment landscape.

   

Based on end-use, the RNA therapeutics market is segmented into hospitals, academic & research institutes, and other end-users. The hospital segment is further divided into public and private.

• Hospital segment dominated the market in 2023 and is anticipated to witness similar trend over the forecast years.

   

• Hospitals are increasingly recognizing the therapeutic potential of RNA-based treatments for a wide range of diseases. Hence, the setting become an epicenter for drugs or vaccine availability, thus supplementing the market growth.

   

• Further, these healthcare settings benefit from established infrastructure along with the presence of trained healthcare professionals, collaboration with public health campaigns, and insurance coverage.

In 2023, North America held a significant share of 36% in the global RNA therapeutics market.
 

• High regional share can be attributed to factors such as robust research and development initiatives, strategic collaborations between pharmaceutical companies and research institutions, and a favorable regulatory environment that supports the advancement of RNA-based therapeutics.

   

• Further, the presence of leading pharmaceutical and biotechnology companies, along with academic institutions engaged in advanced biomedical research, contributes significantly to the region's dominance.
  
   
• Additionally, the region's strong healthcare system and high levels of investment in healthcare technology also play a pivotal role in the widespread adoption of RNA therapeutics, thereby solidifying the region's foothold in this market.